4th Quarter Projections:
Since I've been spot on, on all my projections since the birth of HLIX, I'll continue with more of my keen insight. September 31 ended the third quarter, and I expect to see those results in November (2/3 into our 4th quarter) along with some interesting new developments.
1) I forecast an upgrade to the OTCQB with OTCQB certification. This is just the next logical step as HLIX has endured the test of time, met its price objectives, and remained compliant. This will actually cost an extra $10,000 a year which will be paid for by CSAX's boot from Cannabase.
2) A future partnership to be forged and announced on par with the quality of BiotrackTHC and MJ Freeway, both of which will have proven to be a very significant contribution in the 3rd quarter's results. Momentum is contagious. There is a reason why it pours when it rains. That same reason is behind the inverse relationship to that truth.
3) Expansion into a new state with additional funding in a race to be the Coke or Pepsi in Helix's space, which is perfect as the only "competitors" are all down and trying to recover from near-death experiences. So, kick them while they are down and go ahead and put them down if possible. It's almost impossible to kill a good operator, but since they aren't good operators, just go for the kill shot.
4) An interview with Becky Quick on CNBC. This one is more aggressive for the 4th quarter time slot, but I have to have a high hurdle somewhere (the other 3 I put 95% confidence level on). Since Biotrack and MJ are the two dominant market leaders, since HLIX is the real market leader in its category, yet completely off the radar because they are humble, and because the stock is up over 600% in an emerging high-growth frontier market, it is only a matter of time before CNBC takes notice.
AI
